Last updated: June 11, 2025
Sponsor: AstraZeneca
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Budesonide/glycopyrrolate/formoterol fumarate
Clinical Study ID
NCT06712563
D5980R00084
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients with moderate to severe COPD and initiating BGF treatment according to thelocal prescribing guidance and as per their treating physician's recommendation
Enrolled in on-going single-arm studies
Provided consent for secondary use of data
Exclusion
Exclusion Criteria:
- Did not provide consent for secondary use of data
Study Design
Total Participants: 2000
Treatment Group(s): 1
Primary Treatment: Budesonide/glycopyrrolate/formoterol fumarate
Phase:
Study Start date:
April 17, 2025
Estimated Completion Date:
September 04, 2026
Connect with a study center
Research Site
Mississauga,
CanadaActive - Recruiting
Research Site
Hamburg,
GermanyCompleted
Research Site
Athens,
GreeceSite Not Available
Research Site
Milan,
ItalySite Not Available
Research Site
Tokyo,
JapanCompleted
Research Site
Bucharest,
RomaniaSite Not Available
Research Site
London,
United KingdomCompleted
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.